The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

New Drug for Hearing Loss Approved for Clinical Trials

Research Report
  ()
Plans call for an initial clinical trial to start in H1/23 in both the U.S. and the United Kingdom, where the biopharma recently received approval to proceed, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Biopharma Gains Another Shot on Goal With IND Approval

Research Report
  ()
The firm's CD19- and CD3-targeting monoclonal antibody is now cleared for evaluation in a Phase I clinical trial, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Biopharma Creating COVID Drug Gets US$8.2M From the DOD

Research Report
  ()
This tranche, other cash and cash equivalents, and current cash flow are sufficient to get the developer of immunotherapeutics through 2023, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Biotech's Novel Thin Formulation Improves Veteran-Aiding Treatment

  ()
This morning Awakn Life Sciences announced further details regarding its August 2022 announcement that it had "signed a twelve-month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license a proprietary formulation and route of administration for ketamine." Read to learn more about this announcement, the benefits of this treatment, and what analysts and experts are saying about the company.
Tags:  PsychedelicsBiotechnology / Pharmaceuticals

Exploring Why The Economist Named this Biotech 'One To watch' in 2023

  ()
As more researchers delve into the medicinal potentials of once-verboten compounds, forward-thinking companies like Awakn Life Sciences Corp. are leading the charge to map their most useful aspects and open access for people who need help now. Read more to learn what catalysts Awakn has in store and why The Economist touched on this treatment as one of their top stories of 2023.
Tags:  PsychedelicsHealthcare ServicesBiotechnology / Pharmaceuticals

Biopharma Co.'s Burn Tissue Removal Product Approved

Research Report
  ()
Because of the green light from the U.S. Food and Drug Administration, H.C. Wainwright & Co. raised its target price on the developer of this drug, according to a recent report.
Tags:  Biotechnology / Pharmaceuticals

Tech. Analyst Says Pharma Co. Is at a Favorable Risk/Reward Ratio

Contributed Opinion
  ()
Technical analyst Clive Maund reviews Algernon Pharmaceuticals Inc.'s 6-month, 3-year, and 9-year charts to tell you whether you should be interested in this pharma company.
Tags:  Biotechnology / Pharmaceuticals

Which Precious Metal Has Chen Excited for 2023?

  ()
It's valued the world over as a precious metal, and now it's in demand for the green economy. Which element has asset manager Chen Lin looking forward to the New Year?
Tags:  Critical MetalsSilverBiotechnology / PharmaceuticalsOil & Gas - ServicesOil & Gas - Exploration & Production

Target Price Boosted 400% on Biopharma Co.

Research Report
  ()
The immunotherapy developer also announced positive initial results from the VITALIZE trial in diffuse large B cell lymphoma, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Why One Fund Owns 13% of This Small-Cap Pharma

  ()
Clinical-stage Algernon Pharmaceuticals' multiple pipelines include testing a psychedelic for the treatment of stroke, and testing other drugs for idiopathic pulmonary fibrosis and chronic kidney disease.
Tags:  PsychedelicsBiotechnology / Pharmaceuticals

Showing Results: 26 to 39 of 39 Prev